Peptide Reference
Tirzepatide (Mounjaro)
Tirzepatide
A dual GIP/GLP-1 receptor agonist (Mounjaro) approved for type 2 diabetes with superior glycemic control and weight loss. Now also approved as Zepbound for obesity.
Status
approved
Category
weight loss
Typical cost
$1000-1600/month (brand), $200-500 (compounded)
Mechanism
Activates both GIP and GLP-1 receptors, providing enhanced insulin secretion, glucagon suppression, appetite reduction, and energy expenditure. The dual mechanism produces superior metabolic effects compared to GLP-1 alone.
Potential benefits
- Superior HbA1c reduction up to 2.4%
- Greatest weight loss 20.9%
- Improved lipid profiles
- Enhanced satiety
- Weekly dosing convenience
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
- More GI effects initially
Common dosing references
subcutaneous
2.5-15mg · Weekly
Ongoing
Research notes
SURMOUNT-1 - Tirzepatide for obesity
2022
Unprecedented 20.9% weight loss at 72 weeks with 15mg dose
SURPASS program - Glycemic control
2021
Superior HbA1c reduction compared to all other diabetes medications
Regulatory and sourcing notes
FDA-approved as Mounjaro for diabetes and Zepbound for weight management. Available by prescription.
Prescription required. Highest efficacy GLP-1 available. More GI side effects initially but resolves.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides